Spero Therapeutics, Inc..
SPRO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Spero Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Their pipeline includes SPR206, a direct-acting injectable polymyxin B derivative; tebipenem HBr, an oral carbapenem a...Show More
Better Health for All
0
No evidence available to assess Spero Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Spero Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Spero Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Spero Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
Spero Therapeutics has a formal whistleblower protection policy with anonymous reporting channels available.
1
However, there is no evidence provided regarding independent investigation processes for these reports. The company's code of business conduct and ethics prohibits bribery and kickbacks, including those related to foreign governments or political candidates, in compliance with the FCPA.
2
There is no information on the frequency or effectiveness of training for this policy. The company received a Wells Notice from the SEC in January 2025 regarding public disclosures made in 2022, indicating potential violations of federal securities laws, though no fines have been reported.
3
Kind to Animals
0
No specific, concrete data points or relevant information regarding SPRO.US's performance on any of the 'Kind to Animals' KPIs were found in the provided articles.
1
All articles were generic placeholders and did not contain company-specific evidence.
2
No War, No Weapons
-40
Spero Therapeutics is developing tebipenem HBr, an oral antibiotic primarily for civilian applications such as complicated urinary tract infections (cUTI) and pediatric pneumonia.
1
However, the company has received funding from the Defense Threat Reduction Agency (DTRA) for "nonclinical biodefense aspects" of tebipenem HBr development, indicating that the technology has dual-use potential with both civilian and military applications.
2
This suggests that while the R&D prioritizes civilian uses, military applications are also being considered.
Planet-Friendly Business
20
In 2022, Spero Therapeutics' water consumption was 87,500 gallons per month.
1
With a revenue of $35.2 million in 2022, this translates to approximately 113.06 m³ of water withdrawn per $1 million in revenue.
2
Respect for Cultures & Communities
0
No evidence available to assess Spero Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Spero Therapeutics states it complies with applicable laws and regulations, including GDPR.
1
The company notes that EU/EEA residents have rights to access, rectify, erase, restrict processing, and data portability, with responses provided within four weeks.
2
The company uses secure software encryption (SSL) for its website.
3
Data is retained for the time necessary to fulfill legitimate business purposes, and for LinkedIn/Twitter data, their respective retention policies apply.
4
The company implements technical, administrative, and physical measures to protect data.
5
Zero Waste & Sustainable Products
-40
Spero Therapeutics achieved a 17.5% reduction in non-hazardous waste through recycling in 2022.
1
The company generated 3.8 metric tons of hazardous waste in 2022, incurring a disposal cost of $173,280.
2
Additionally, 6.2 metric tons of research waste were generated in 2022, with 42% of this being biodegradable.
3